CAS No.:209216-23-9

TOXICITY DATA with REFERENCE：

 

Consensus Reports：

 

SAFETY PROFILE：

 Entecavir hydrate (CAS NO.209216-23-9)  may cause lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) when used alone or in combination with antiretrovirals. Severe acute hepatitis B exacerbations have occurred in patients who discontinued anti-hepatitis B therapy, including entecavir. Monitor hepatic function for at least several months after discontinuation. If appropriate, initiate anti-hepatitis B therapy.

Standards and Recommendations：

 

Analytical Methods：